'Au­ton­o­my with bridges': The chief ar­chi­tect of the Alex­ion buy­out is now head­ed over to take com­mand. Here's what he's think­ing

As­traZeneca CEO Pas­cal So­ri­ot has made it clear that he has a lot more in mind for new­ly pur­chased Alex­ion than soak­ing up the fran­chise drug side of the busi­ness and adding it to the phar­ma gi­ant’s rev­enue stream — while chop­ping costs down to pay for the deal. And now he’s putting one of the chief ar­chi­tects of the deal in place as the new CEO of Alex­ion.

The Big Phar­ma an­nounced this morn­ing that it’s ex­e­cut­ing a trade of sorts be­tween the teams of the two com­pa­nies. Sub­ject to a for­mal clo­sure of the deal, sanc­tioned by the FTC now, So­ri­ot is send­ing his CFO Marc Dunoy­er over to the Boston com­pa­ny while tak­ing Alex­ion CFO Arad­hana Sarin as the new num­bers chief at As­traZeneca.

Dunoy­er al­so be­comes As­traZeneca’s chief strat­e­gy of­fi­cer, giv­ing him a big role in the deals to come.

I spoke with Dunoy­er about the Alex­ion deal a few weeks ago, ahead of this ex­ec­u­tive suite shake­up. In a close­ly fo­cused con­ver­sa­tion, Dunoy­er ex­plained how As­traZeneca nar­rowed a wide-rang­ing M&A search down to Alex­ion, of­fer­ing some in­sights on the role Alex­ion will play as the com­pa­ny’s new cen­ter for rare dis­eases. What fol­lows is the Q&A we had, edit­ed for length and clar­i­ty.

I start­ed by ask­ing how As­traZeneca de­cid­ed to go af­ter Alex­ion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER